![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
Katryn Allen is currently a method development scientist at the PRA Health Sciences Bioanalytical Laboratory in Lenexa, Kansas. Katryn has over 5 years of pharmaceutical industry experience in bioanalytical method development and in the preclinical environment. While at PRA, she has developed ligand-binding assays for pharmacokinetic, pharmacodynamics and immunogenicity end points. She received her PhD in toxicology from the University of Kansas Medical Centre (KS, USA) in 2011.
Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Science Group.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.